Human Haemophilus Influenza B IgG ELISA Kit

Sample

Serum, plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

Human Haemophilus Influenza B IgG ELISA is an enzyme immunoassay for determination of IgG antibodies against polyribosylribitol phosphate of Haemophilus influenzae type B in human serum and plasma.

Contents of Kit

1. 1 × 12 × 8 Microtiter Plate: Coated with PRP from Haemophilus influenzae Typ B. Ready to use!
2. 1 × 0.3 mL Enzyme Conjugate, Concentrate: Anti-human-IgG-peroxidase; colored blue. Dilute before use!
3. 5 × 0.35 mL Standard 1-5, Concentrate (NISBC code 09/222): Human sera with stabilizers and preservatives. Concentrations are lot specific as indicated on the bottle labels. Dilute before use!
4. 2 × 0.35 mL Positive Control LL+HL, Concentrate: Positive control sera, LL, "Low Level", HL, "High Level"; for testing accuracy; human sera with stabilizers and preservatives. Concentrations are lot specific as indicated on the bottle labels. Dilute before use!
5. 2 × 50 mL Incubation Buffer (Dilution Buffer): phosphate buffer, contains detergent and ProClin-300; colored red. Ready to use!
6. 1 × 50 mL Wash Buffer, Concentrate (20x): Contains: phosphate buffer.
7. 1 × 12 mL TMB Substrate Solution: Substrate solution contains TMB (tetramethylbenzidine). Ready to use!
8. 1 × 12 mL TMB Stop Solution: Stop solution, 0.5 M sulphuric acid. Ready to use!
9. Adhesive Foi: 2 pieces.

Storage

Store the kit at 4°C upon receipt. For more detailed information, please download the following document on our website.

Precision

Intra-assay variation: ≤ 10%
Inter-assay variation: 5% - 15%

General Description

Haemophilus influenzae type B (HiB) is a very common cause of invasive critical infectious diseases in children up to the age of six. Following infection the symptoms of the disease include: Pericarditis, osteomyelitis, meningitis, encephalitis, pneumonia, sinusitis and otitis. In many cases the disease is lethal or leads to neurological damage, which cannot always be prevented by rapid antibiotic therapy. The underlying reason for the disease is very often a latent immunodeficiency with a specifically reduced humoral immune response to the polyribosylribitol phosphate (PRP) in the polysaccharide encapsulation of the bacterium. In children another reason is the immaturity of the immune system. Today often the term "immunocompromised patients" is used,comprising all acquired and innate specific and unspecific immunodeficiencies.
As a result, in children of 3 months of age or older a vaccination with different sorts of PRP-containing vaccines is recommended. This can lead to a clear reduction in the number of infections with Haemophilus influenzae type B.The titer of antibodies produced by vaccination can be used to confirm whether the vaccination has been successful. The HiB IgG is used to measure the level of PRP-specific IgG-antibodies following a 4-6 week period after complete immunization to monitor the humoral immune status of children or other individuals at risk.
Monitoring of the humoral immunostatus after vaccination. Verification of the diagnosis Haemophilus influenzae type B infection by repeated monitoring of antibody concentrations. Risk assessment in immunocompromised patients leading to a failure of vaccination with a PRP-containing vaccine.